Published Online
on February 13, 2006

A more recent version of this article appeared on February 21, 2006

This Article Full Text (PDF) All Versions of this Article: 113/7/977    most recent CIRCULATIONAHA.105.567727v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, M. E. Articles by Troughton, R. W. Search for Related Content PubMed PubMed Citation Articles by Davis, M. E. Articles by Troughton, R. W. Related Collections Congestive Cardiovascular Pharmacology

Submitted on June 13, 2005
Revised on November 13, 2005
Accepted on December 16, 2005

Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure

Mark E. Davis MBChB^*, A. Mark Richards MD, M. Gary Nicholls MD, Timothy G. Yandle PhD, Christopher M. Frampton PhD, and Richard W. Troughton MD

From the Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand.

^* To whom correspondence should be addressed. E-mail: mark.davis{at}chmeds.ac.nz.

Background--The effect of -blockade on the cardiac natriuretic peptides is poorly understood but could contribute to their beneficial treatment effect and may be relevant to clinical use of plasma brain natriuretic peptide (BNP)/N-terminal pro brain natriuretic peptide (NTproBNP) measurements in risk stratification and in titration of anti-heart failure therapy.

Methods and Results--Sixteen men with mild, stable heart failure (NYHA class II to III; left ventricular ejection fraction <40%) underwent serial blood sampling for plasma natriuretic peptide levels and received infusions of atrial natriuretic peptide (ANP) and BNP before and 6 weeks after the introduction and uptitration of metoprolol or 6 weeks unchanged therapy in a randomized, parallel-group design. Plasma natriuretic peptides (BNP, NTproBNP, ANP, and NTproANP) were increased by metoprolol (P<0.01 for all). The natriuretic responses to ANP and BNP infusions were sustained with the introduction of metoprolol despite reduced renal perfusion pressure. The levels of the noninfused natriuretic peptide were increased by both ANP and BNP infusions, and this effect was enhanced by metoprolol. The early plasma half-life (t1\2>) of BNP was prolonged by metoprolol (5.6±0.45 to 11±1.3 versus 5.7±0.8 to 6.6±1.3 minutes in control subjects; P=0.019).

Conclusions--Plasma cardiac natriuretic peptide levels increase significantly with the introduction of metoprolol in heart failure as a result of effects on secretion and clearance. Natriuretic responses to NP infusions are sustained with -blockade despite reduced renal perfusion pressure. Clinicians should be aware that the introduction of metoprolol causes a rise in plasma BNP/NTproBNP that is unrelated to deterioration in clinical status and must be considered when measurements are undertaken for risk stratification or titration of treatment.

Key words: heart failure • natriuretic peptides • receptor blockers, adrenergic, beta

This article has been cited by other articles:

				R. Tagore, L. H. Ling, H. Yang, H.-Y. Daw, Y.-H. Chan, and S. K. Sethi Natriuretic Peptides in Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1644 - 1651. [Abstract] [Full Text] [PDF]

				D. Moertl, A. Hammer, M. Huelsmann, R. Pacher, and R. Berger Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients Eur J Heart Fail, April 1, 2008; 10(4): 404 - 411. [Abstract] [Full Text] [PDF]

				L. G. Olsson, K. Swedberg, J. G.F. Cleland, P. A. Spark, M. Komajda, M. Metra, C. Torp-Pedersen, W. J. Remme, A. Scherhag, P. Poole-Wilson, et al. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a {beta}-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial Eur J Heart Fail, August 1, 2007; 9(8): 795 - 801. [Abstract] [Full Text] [PDF]

				W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF]

				R. Carrillo-Jimenez, S. Borzak, and C. H. Hennekens Brain Natriuretic Peptide: Clinical and Research Challenges Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 85 - 88. [Abstract] [PDF]

				N. C Van Pelt, R. A H Stewart, M. E Legget, G. A Whalley, S. P Wong, I. Zeng, M. Oldfield, and A. J Kerr Longitudinal left ventricular contractile dysfunction after exercise in aortic stenosis Heart, June 1, 2007; 93(6): 732 - 738. [Abstract] [Full Text] [PDF]

				R. Berger, D. Moertl, M. Huelsmann, A. Bojic, R. Ahmadi, I. Heissenberger, and R. Pacher Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure Eur J Heart Fail, February 1, 2007; 9(2): 202 - 208. [Abstract] [Full Text] [PDF]

				S. Masson, R. Latini, I. S. Anand, T. Vago, L. Angelici, S. Barlera, E. D. Missov, A. Clerico, G. Tognoni, J. N. Cohn, et al. Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data Clin. Chem., August 1, 2006; 52(8): 1528 - 1538. [Abstract] [Full Text] [PDF]